spec sheet12 rows
Apremilast (Otezla) is an orally active PDE4 inhibitor and the first PDE4 drug ever FDA-approved for an immune-dermatologic indication (2014). By raising intracellular cAMP it recalibrates the immune system from the inside out, dialing down TNF-alpha, IL-23 and IL-17 while lifting anti-inflammatory IL-10. That single, elegant switch clears plaque psoriasis, calms psoriatic arthritis, and heals Behcet's oral ulcers, all from a convenient oral tablet that needs no lab monitoring.
- Clears plaque psoriasis and calms psoriatic arthritis from a convenient oral tablet
- Heals Behcet's-associated oral ulcers
- No routine laboratory monitoring required, unlike many biologics and immunosuppressants
- Rebalances immune signaling by raising cAMP rather than broadly suppressing immunity
- Labeled depression and suicidality warning (0.2% incidence in trials)
- Early GI effects: diarrhea, nausea, vomiting
- Weight loss of 5-10% in roughly 10% of users
- Headache; efficacy blunted by strong CYP3A4 inducers
- It was the first PDE4 inhibitor ever approved by the FDA for an immune or dermatologic condition.
- Unlike thalidomide analogues, apremilast does not bind cereblon at all, which is why it lacks their teratogenic mechanism.
- Its wide emesis window (demonstrated in ferrets) is a big part of why it is tolerable orally where earlier PDE4 drugs failed.
Mechanism
Inhibits PDE4A-D with an IC50 near 10-100 nM and no other PDE, kinase or receptor activity, raising and driving PKA to /ATF-1 while suppressing NF-kB. The net effect lowers TNF-alpha, IL-23 and IL-17 and raises IL-10. Unlike thalidomide relatives it does not bind cereblon.
receptor fingerprint
PDE4 (A/B/C/D)Inhibits
TNF-alphaSuppresses
IL-23 / IL-17Reduces
IL-10Increases
NF-kBInhibits
Evidencehow good the literature is
Human RCT evidence is proven for its approved uses: multiple Phase 3 trials in plaque psoriasis, psoriatic arthritis and Behcet's oral ulcers. Cognition evidence is preclinical only. Rodent studies show memory rescue plus amyloid and tau reduction in Alzheimer-like diabetic rats, and stroke and blood-brain-barrier protection. In vitro it raises cAMP/CREB/ATF-1 and suppresses NF-kB. There are no human cognition trials.
Safetyrisks and cautions, not medical advice
Truthfully, apremilast carries a labeled depression and suicidality warning: suicidal ideation or behavior occurred in 0.2% (3/1441) versus 0/495 on placebo. GI class effects (diarrhea, nausea, vomiting) appear early, weight loss of 5-10% affects around 10% of users, and headache is common. It is CYP3A4-metabolized, so strong inducers such as rifampin (which cut exposure by 72%), carbamazepine, phenytoin and St. John's wort reduce efficacy and are not recommended. Cognitive use is off-label and unproven.
Interactionsdocumented pairs only, not exhaustive
Apremilast has an unusually quiet interaction profile, and one interaction that genuinely matters.
It is cleared principally by CYP3A4. Strong inducers strip that exposure away: rifampin given for fifteen days reduced apremilast AUC by about 72 percent and peak concentration by about 43 percent in healthy volunteers, which is enough to lose the drug's effect entirely. Phenytoin, carbamazepine, phenobarbital, rifabutin and St John's wort act by the same mechanism, and the pairing is not recommended for that reason.
The opposite direction is undramatic. Ketoconazole, a strong CYP3A4 inhibitor, raises apremilast exposure only modestly, and the change has not been judged clinically meaningful.
Dedicated studies found no meaningful interaction with methotrexate or with oral contraceptives containing ethinyl estradiol and norgestimate, which covers the two combinations most likely to arise in psoriasis and psoriatic arthritis. Apremilast is not a clinically relevant inhibitor or inducer of the major CYP enzymes itself, so it does little to the drugs around it.
Checking a whole stack? Run it through interactions + stacks.
History
Developed by Celgene as CC-10004 and approved by the FDA in 2014 (Otezla) for psoriatic arthritis and plaque psoriasis, it became the first oral PDE4 inhibitor to reach the immune-dermatologic market. Approval for Behcet's-associated oral ulcers followed in 2019. Amgen acquired the franchise the same year in one of the largest single-product deals in the sector.
Reputation
Widely regarded as a well-tolerated oral alternative to injectable biologics and classic immunosuppressants, prized for needing no routine lab monitoring. Among nootropic enthusiasts it draws curiosity for its cAMP/CREB mechanism, but that interest runs well ahead of the evidence, which remains preclinical.
Subjective profileweighing the evidence above
A genuinely approved, well-characterized anti-inflammatory PDE4 drug with a clean oral profile and strong Phase 3 data across psoriasis, psoriatic arthritis and Behcet's disease. Its nootropic reputation, however, is entirely speculative and animal-only, and the label carries a real depression and suicidality warning that must be taken seriously.
Resources
This entry is here for reference.
Research
- 2014first citedApremilast is a selective PDE4 inhibitor with regulatory effects on innate immunity.
- 2015controlled trialApremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe p…
- 2025most recentSafety assessment of apremilast: real-world adverse event analysis from the FAERS database.
- 1.Apremilast is a selective PDE4 inhibitor with regulatory effects on innate immunity.
- 2.Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: Results of a phase III, randomized, controlled trial (Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis [ESTEEM] 1).
- 3.Trial of Apremilast for Oral Ulcers in Behçet's Syndrome.
- 4.Intermittent treatment with Apremilast, a phosphodiesterase-4 inhibitor, ameliorates Alzheimer's-like pathology and symptoms through multiple targeting actions in aged T2D rats.
- 5.Safety assessment of apremilast: real-world adverse event analysis from the FAERS database.
5 listed here; entry last updated August 2026
Reviews
My notesprivate to this device
FAQ
Is apremilast a proven cognitive enhancer?
No. Its cognition data are entirely preclinical (rodent Alzheimer models). Human evidence exists only for its approved immune and dermatologic uses.
Does it require blood-test monitoring?
No routine lab monitoring is mandated, which is a key convenience advantage over biologics and classic immunosuppressants.
What is the most important safety caveat?
The label carries a depression and suicidality warning; anyone with a mood-disorder history should be monitored and discuss it with a clinician.
Adverse effects
- Labeled depression and suicidality warning (0.2% incidence in trials)
- Early GI effects: diarrhea, nausea, vomiting
- Weight loss of 5-10% in roughly 10% of users
- Headache; efficacy blunted by strong CYP3A4 inducers